Targeted cancer treatments are associated with on-target and off-target AEs.42 On-target AEs with amivantamab include skin and gastrointestinal reactions associated with EGFR inhibition and peripheral edema, hypoalbuminemia, and transaminase elevation associated with MET inhibition (Figure 1).29,44-46 Additionally, IV amivantamab, as with other infused therapies, can be associated with infusion-related reactions (IRRs), with symptoms including chills, nausea, shortness of breath, hypotension, and rash.47,48. The gene discussed is EGFR; the disease is Hypoalbuminemia.